<?xml version='1.0' encoding='utf-8'?>
<document id="31992459"><sentence text="Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State."><entity charOffset="54-67" id="DDI-PubMed.31992459.s1.e0" text="Lobeglitazone" /><entity charOffset="72-85" id="DDI-PubMed.31992459.s1.e1" text="Dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s1.e0" e2="DDI-PubMed.31992459.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s1.e0" e2="DDI-PubMed.31992459.s1.e1" /></sentence><sentence text="Coadministration of lobeglitazone and dapagliflozin is expected to result in a blood glucose-lowering effect, followed by a gradual increase, in clinical usage; however, combining drugs could cause negative interactions"><entity charOffset="20-33" id="DDI-PubMed.31992459.s2.e0" text="lobeglitazone" /><entity charOffset="38-51" id="DDI-PubMed.31992459.s2.e1" text="dapagliflozin" /><entity charOffset="85-92" id="DDI-PubMed.31992459.s2.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.31992459.s2.e0" e2="DDI-PubMed.31992459.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s2.e0" e2="DDI-PubMed.31992459.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s2.e0" e2="DDI-PubMed.31992459.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31992459.s2.e1" e2="DDI-PubMed.31992459.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s2.e1" e2="DDI-PubMed.31992459.s2.e2" /></sentence><sentence text=" This study aimed to evaluate the effect of the coadministration of lobeglitazone and dapagliflozin on their individual pharmacokinetic properties at steady state in healthy male volunteers in the fasted state"><entity charOffset="68-81" id="DDI-PubMed.31992459.s3.e0" text="lobeglitazone" /><entity charOffset="86-99" id="DDI-PubMed.31992459.s3.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s3.e0" e2="DDI-PubMed.31992459.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s3.e0" e2="DDI-PubMed.31992459.s3.e1" /></sentence><sentence text="" /><sentence text="This study consisted of 2 parts, each of which was a randomized, open-labeled, multiple-dose, 2-way crossover study in 20 healthy male volunteers in each part" /><sentence text=" Blood samples were taken periodically over a 48-h period after dosing to derive total plasma lobeglitazone and dapagliflozin pharmacokinetic properties; safety profile was evaluated throughout the study"><entity charOffset="94-107" id="DDI-PubMed.31992459.s6.e0" text="lobeglitazone" /><entity charOffset="112-125" id="DDI-PubMed.31992459.s6.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s6.e0" e2="DDI-PubMed.31992459.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s6.e0" e2="DDI-PubMed.31992459.s6.e1" /></sentence><sentence text="" /><sentence text="When the pharmacokinetic properties of dapagliflozin were evaluated following its administration alone and in combination with lobeglitazone, point estimate and 90% CI of the geometric mean ratio of dapagliflozin AUCτ were entirely within the conventional bioequivalence range of 80%-125%"><entity charOffset="39-52" id="DDI-PubMed.31992459.s8.e0" text="dapagliflozin" /><entity charOffset="127-140" id="DDI-PubMed.31992459.s8.e1" text="lobeglitazone" /><entity charOffset="199-212" id="DDI-PubMed.31992459.s8.e2" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s8.e0" e2="DDI-PubMed.31992459.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s8.e0" e2="DDI-PubMed.31992459.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s8.e0" e2="DDI-PubMed.31992459.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31992459.s8.e1" e2="DDI-PubMed.31992459.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s8.e1" e2="DDI-PubMed.31992459.s8.e2" /></sentence><sentence text=" However, although it was not clinically meaningful, its Css,max was ~8% lower in subjects receiving multiple doses of dapagliflozin and lobeglitazone than that in those administered dapagliflozin alone"><entity charOffset="119-132" id="DDI-PubMed.31992459.s9.e0" text="dapagliflozin" /><entity charOffset="137-150" id="DDI-PubMed.31992459.s9.e1" text="lobeglitazone" /><entity charOffset="183-196" id="DDI-PubMed.31992459.s9.e2" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s9.e0" e2="DDI-PubMed.31992459.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s9.e0" e2="DDI-PubMed.31992459.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s9.e0" e2="DDI-PubMed.31992459.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31992459.s9.e1" e2="DDI-PubMed.31992459.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31992459.s9.e1" e2="DDI-PubMed.31992459.s9.e2" /></sentence><sentence text=" The pharmacokinetic properties of lobeglitazone were evaluated following its administration alone and in combination with dapagliflozin"><entity charOffset="35-48" id="DDI-PubMed.31992459.s10.e0" text="lobeglitazone" /><entity charOffset="123-136" id="DDI-PubMed.31992459.s10.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s10.e0" e2="DDI-PubMed.31992459.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s10.e0" e2="DDI-PubMed.31992459.s10.e1" /></sentence><sentence text=" The geometric mean ratios and 90% CIs of the lobeglitazone Css,max and AUCτ were within the conventional bioequivalence range of 80%-125%"><entity charOffset="46-59" id="DDI-PubMed.31992459.s11.e0" text="lobeglitazone" /></sentence><sentence text="" /><sentence text="Coadministration of lobeglitazone and dapagliflozin had no apparent clinically relevant effects on the pharmacokinetic properties of either drug"><entity charOffset="20-33" id="DDI-PubMed.31992459.s13.e0" text="lobeglitazone" /><entity charOffset="38-51" id="DDI-PubMed.31992459.s13.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s13.e0" e2="DDI-PubMed.31992459.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s13.e0" e2="DDI-PubMed.31992459.s13.e1" /></sentence><sentence text=" Based on these findings, it is anticipated that lobeglitazone and dapagliflozin can be coadministered without dose adjustment"><entity charOffset="49-62" id="DDI-PubMed.31992459.s14.e0" text="lobeglitazone" /><entity charOffset="67-80" id="DDI-PubMed.31992459.s14.e1" text="dapagliflozin" /><pair ddi="false" e1="DDI-PubMed.31992459.s14.e0" e2="DDI-PubMed.31992459.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31992459.s14.e0" e2="DDI-PubMed.31992459.s14.e1" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT03616392" /><sentence text="" /></document>